Torisel (Temsirolimus)
Selective mTOR inhibitor for advanced renal cell carcinoma and mantle cell lymphoma
Torisel (temsirolimus) is an anticancer medication that works by selectively inhibiting the mTOR enzyme, a key regulator of tumor cell growth and division. It is approved for the treatment of advanced renal cell carcinoma (kidney cancer) and previously treated mantle cell lymphoma. Administered as a weekly intravenous infusion under medical supervision, Torisel requires premedication with an antihistamine to reduce the risk of allergic reactions.
Quick Facts
Key Takeaways
- Torisel (temsirolimus) is used to treat advanced renal cell carcinoma and previously treated mantle cell lymphoma in adults.
- It is given as a weekly intravenous infusion over 30 to 60 minutes in a clinical setting; patients receive antihistamine premedication before each dose.
- Common side effects include weakness, infections, rash, nausea, high blood sugar, high cholesterol, and reduced blood cell counts requiring regular monitoring.
- Major drug interactions include strong CYP3A4 inhibitors (azole antifungals) and CYP3A4 inducers (rifampin, carbamazepine, St. John's wort); grapefruit juice must be avoided.
- Effective contraception is required for both women and men during treatment; Torisel must not be used during pregnancy or breastfeeding.
What Is Torisel and What Is It Used For?
Torisel contains the active substance temsirolimus, a selective inhibitor of the enzyme known as mTOR (mammalian target of rapamycin). The mTOR pathway plays a central role in regulating cell growth, proliferation, and survival. In many cancers, this pathway is abnormally activated, leading to uncontrolled cell division. Temsirolimus works by binding to an intracellular protein called FKBP-12, forming a complex that inhibits mTOR kinase activity, thereby blocking the signals that drive tumor growth.
By inhibiting mTOR, temsirolimus exerts multiple anticancer effects. It arrests tumor cells in the G1 phase of the cell cycle, preventing them from dividing further. Additionally, it reduces levels of hypoxia-inducible factors (HIFs), which are proteins that promote the formation of new blood vessels (angiogenesis) that tumors need to grow. This dual mechanism of action—inhibiting both cell proliferation and angiogenesis—makes temsirolimus effective against cancers that are particularly dependent on these processes.
Torisel is specifically approved for two types of cancer in adults. The first indication is advanced renal cell carcinoma (kidney cancer), where it is used as a first-line treatment in patients with poor prognostic features. Clinical trials, most notably the Global ARCC trial published in the New England Journal of Medicine, demonstrated that temsirolimus significantly improved overall survival compared to interferon-alpha alone in patients with previously untreated, advanced renal cell carcinoma and at least three of six prognostic risk factors.
The second approved indication is relapsed or refractory mantle cell lymphoma (MCL), a relatively rare and aggressive type of non-Hodgkin lymphoma that affects the lymph nodes. In patients whose disease has returned after or failed to respond to prior therapy, Torisel offers a treatment option that targets the molecular pathways driving lymphoma cell survival. The drug is administered at a higher initial dose for MCL compared to renal cell carcinoma, reflecting the different biology and treatment requirements of these two cancers.
It is important to understand that Torisel is not a cure for these cancers. Rather, it is used to slow disease progression, shrink tumors, and extend survival. Treatment continues as long as the patient is benefiting from the therapy and side effects remain manageable. Your oncologist will regularly assess your response to treatment through imaging studies and blood tests.
What Should You Know Before Taking Torisel?
Contraindications
There are specific situations in which Torisel must not be used. You should not receive this medication if you have a known allergy (hypersensitivity) to temsirolimus, to polysorbate 80 (an excipient used in the formulation), or to any of the other ingredients. Because temsirolimus is metabolized in the body to produce sirolimus (also known as rapamycin), patients who are allergic to sirolimus—a drug used to prevent rejection of transplanted kidneys—must also avoid Torisel.
Additionally, patients with mantle cell lymphoma who have liver problems must not receive Torisel. Hepatic impairment can significantly alter the way the drug is processed in the body, potentially leading to dangerously elevated drug levels and an increased risk of severe toxicity. For patients with renal cell carcinoma, dose adjustments may be considered in the presence of mild hepatic impairment, but treatment decisions should always be made by an experienced oncologist.
Warnings and Precautions
Before starting treatment with Torisel, it is essential to discuss your complete medical history with your healthcare provider. Several conditions and situations require special attention and careful monitoring throughout treatment.
Hypersensitivity reactions, including potentially life-threatening anaphylaxis, have been reported with Torisel. An antihistamine must be administered intravenously approximately 30 minutes before each infusion. If you cannot tolerate antihistamines for any medical reason, discuss alternatives with your doctor before starting treatment. If you experience swelling of the face, tongue, or throat, or have difficulty breathing during infusion, alert your healthcare team immediately.
Infections and immune suppression: Torisel weakens the immune system, increasing the risk of infections including pneumonia, urinary tract infections, skin infections, and bloodstream infections (sepsis). Some of these infections can be serious or life-threatening. Tell your doctor immediately if you develop fever, cough, shortness of breath, or any new symptoms of infection during treatment. Patients should generally avoid live vaccines during treatment as the immune response may be reduced and the vaccine could potentially cause the very infection it is meant to prevent.
Interstitial lung disease (pneumonitis): Torisel can cause a non-infectious inflammation of the lungs known as interstitial pneumonitis. This condition may present with cough, shortness of breath, chest pain, or fever, though some patients have minimal or no symptoms. Your doctor may recommend chest CT scans or X-rays before and during treatment to monitor for this potentially serious complication. If pneumonitis develops, treatment may need to be interrupted or discontinued depending on the severity.
Bleeding and blood disorders: Torisel can reduce the number of platelets (cells responsible for blood clotting) and white blood cells in the body. Low platelet counts increase the risk of bleeding and bruising, while low white blood cell counts increase vulnerability to infections. Regular blood tests will be performed during treatment to monitor these cell counts. Patients with brain or spinal cord tumors, existing bleeding problems, or those taking anticoagulant medications (such as warfarin) may be at increased risk of cerebral hemorrhage (brain bleeding).
Metabolic effects: Torisel frequently causes elevated blood sugar levels (hyperglycemia), which may worsen existing diabetes mellitus or trigger new-onset diabetes. Patients may require treatment with insulin or oral antidiabetic agents. The drug also commonly increases blood levels of cholesterol and triglycerides, which may necessitate lipid-lowering medications. Regular monitoring of blood glucose and lipid levels is essential throughout treatment.
Kidney function: Abnormal kidney function, including acute kidney failure, has been reported in patients treated with Torisel. Your doctor will monitor kidney function through regular blood tests. Report any generalized swelling, decreased urine output, or unusual fatigue to your healthcare provider.
Wound healing: Torisel may impair wound healing. If you are scheduled for surgery, treatment will typically be interrupted before the procedure. Your doctor will determine when it is safe to resume treatment after the wound has healed adequately.
Patients over 65 years: Elderly patients may be at increased risk of certain side effects, including facial swelling, diarrhea, pneumonia, anxiety, depression, shortness of breath, decreased white blood cell count, muscle pain, taste changes, upper respiratory tract infections, pleural effusion, and mouth ulcers.
Torisel contains ethanol (alcohol). At the standard 25 mg dose for renal cell carcinoma, the amount of alcohol is relatively small (equivalent to approximately 18 ml of beer). However, at the higher 175 mg initial dose used for mantle cell lymphoma, the alcohol content is significantly higher (equivalent to approximately 122 ml of beer per dose). This should be considered by patients with alcohol dependency, liver disease, epilepsy, or who are pregnant or breastfeeding.
Pregnancy and Breastfeeding
Torisel has not been studied in pregnant women and must not be used during pregnancy unless the potential benefit clearly justifies the risk to the fetus. Animal studies have shown reproductive toxicity, including embryo-fetal lethality and developmental abnormalities.
Women of childbearing potential must use effective contraception throughout the course of treatment and for a period after the last dose as advised by their physician. Male patients with female partners of childbearing potential should also use medically acceptable contraception during treatment.
Women must not breastfeed during treatment with Torisel, as it is unknown whether temsirolimus or its metabolites are excreted in breast milk. Given the potential for serious adverse effects in nursing infants, breastfeeding must be discontinued before starting treatment.
Children and Adolescents
Torisel is not intended for use in children and adolescents under 18 years of age. The approved indications—advanced renal cell carcinoma and mantle cell lymphoma—are conditions that primarily affect adults, and there is insufficient clinical data to support the safety and efficacy of temsirolimus in pediatric patients.
How Does Torisel Interact with Other Drugs?
Drug interactions are a critical consideration with Torisel because temsirolimus is primarily metabolized by the liver enzyme CYP3A4. Medications that either inhibit or induce this enzyme can significantly alter the blood levels of temsirolimus and its active metabolite sirolimus, potentially reducing effectiveness or increasing toxicity. Always inform your oncologist about all medications you are taking, including prescription drugs, over-the-counter products, herbal supplements, and dietary supplements.
Major Interactions
| Interacting Drug/Class | Effect | Clinical Significance |
|---|---|---|
| Ketoconazole, Itraconazole, Voriconazole (azole antifungals) | Strong CYP3A4 inhibition increases temsirolimus blood levels | Increased risk of severe toxicity; dose reduction required if co-administration cannot be avoided |
| HIV Protease Inhibitors (ritonavir, nelfinavir) | Strong CYP3A4 inhibition increases temsirolimus blood levels | Co-administration should be avoided or dose adjustment required |
| Rifampin (rifampicin) | Strong CYP3A4 induction decreases temsirolimus blood levels | Reduced anticancer efficacy; dose increase may be necessary |
| Carbamazepine, Phenytoin, Phenobarbital (antiepileptics) | CYP3A4 induction decreases temsirolimus blood levels | Reduced effectiveness; consider alternative anticonvulsants |
| St. John's wort (Hypericum perforatum) | CYP3A4 induction decreases temsirolimus blood levels | Must be avoided during treatment with Torisel |
| Sunitinib | Increased toxicity when combined | Dose-limiting toxicities observed in clinical trials; combination not recommended |
Other Notable Interactions
ACE inhibitors (enalapril, ramipril, lisinopril) and calcium channel blockers (amlodipine): Co-administration with Torisel may increase the risk of angioedema (swelling of the face, lips, tongue, or throat). Patients taking these cardiovascular medications should be monitored carefully and should immediately report any signs of swelling.
Nefazodone and SSRIs: These antidepressants may inhibit CYP3A4 and increase temsirolimus levels to varying degrees. Discuss alternative antidepressant options with your doctor if needed.
Amiodarone and statins: Amphiphilic drugs used for heart rhythm disorders and lipid-lowering statins may interact with temsirolimus. Monitoring for increased side effects is recommended.
P-glycoprotein substrates: Temsirolimus may affect the blood levels of drugs that are substrates of the P-glycoprotein transporter, including digoxin, vincristine, colchicine, dabigatran, lenalidomide, and paclitaxel. Dose adjustments of these medications may be necessary.
Cannabidiol (CBD): Cannabidiol, used among other indications for the treatment of epileptic seizures, may interact with Torisel through CYP3A4 inhibition. Inform your doctor if you are using CBD products.
Grapefruit and grapefruit juice can increase blood concentrations of temsirolimus by inhibiting CYP3A4 in the gut wall. Patients receiving Torisel should completely avoid grapefruit and grapefruit juice throughout their treatment course.
What Is the Correct Dosage of Torisel?
Torisel must always be prepared and administered by a healthcare professional in a clinical setting. The drug is given as an intravenous infusion (drip into a vein) and should never be self-administered. Before each dose, an antihistamine is injected intravenously approximately 30 minutes prior to the Torisel infusion to prevent potential allergic reactions.
Adults — Advanced Renal Cell Carcinoma
Standard Dose
25 mg administered as an intravenous infusion over 30 to 60 minutes, once weekly. Treatment continues until disease progression or unacceptable toxicity occurs. The concentrate must first be diluted with 1.8 ml of the provided diluent to achieve a concentration of 10 mg/ml, then further diluted in 250 ml of 0.9% sodium chloride solution for infusion.
Adults — Mantle Cell Lymphoma
Induction Phase (Weeks 1–3)
175 mg administered as an intravenous infusion over 30 to 60 minutes, once weekly for 3 weeks. Multiple vials are required for each dose at this level.
Maintenance Phase (Week 4 onward)
75 mg administered as an intravenous infusion over 30 to 60 minutes, once weekly. Treatment continues until disease progression or unacceptable toxicity.
Children
Torisel is not recommended for use in children and adolescents under 18 years of age due to lack of clinical data supporting safety and efficacy in this population.
Elderly
No specific dose adjustment is required for elderly patients. However, patients over 65 years may be more susceptible to certain side effects and should be monitored closely throughout treatment. Dose modifications may be necessary based on individual tolerability.
Dose Modifications
Your oncologist may adjust your dose based on how well you tolerate the treatment. Dose reductions or temporary treatment interruptions may be necessary for managing significant side effects such as severe neutropenia, thrombocytopenia, or other grade 3–4 adverse events. When Torisel is co-administered with strong CYP3A4 inhibitors that cannot be avoided, a dose reduction should be considered. Conversely, when used with strong CYP3A4 inducers, a dose increase may be warranted.
Missed Dose
Since Torisel is administered by a healthcare professional in a clinical setting, missed doses are unlikely. However, if an appointment is missed, contact your oncology team as soon as possible to reschedule. Do not receive a double dose to make up for a missed infusion.
Overdose
As Torisel is prepared and administered by healthcare professionals, overdose is unlikely. There is no specific antidote for temsirolimus overdose. In the event of an overdose, treatment would be supportive and symptomatic. If you suspect that you received more than your prescribed dose, inform your healthcare team immediately.
What Are the Side Effects of Torisel?
Like all medicines, Torisel can cause side effects, although not everyone experiences them. Side effects may be more pronounced with the higher 175 mg weekly dose used during the initial treatment phase for mantle cell lymphoma. Your medical team will monitor you closely and can adjust treatment if necessary.
- Allergic reactions: Swelling of face, tongue, or throat; difficulty breathing. The infusion will be stopped immediately.
- Cerebral hemorrhage: Confusion, unusual tiredness, difficulty speaking or swallowing, unequal pupil size.
- Intestinal perforation: Severe abdominal pain, high fever, nausea, vomiting, or blood in stool.
- Kidney failure: Generalized swelling, difficulty breathing, extreme fatigue.
- Pulmonary embolism: Sudden shortness of breath, chest pain, coughing up blood, rapid heart rate, sweating, bluish skin.
Very Common
Affects more than 1 in 10 patients
- General weakness, chills, swelling (edema), pain (abdominal, back, chest, joint)
- Nausea, vomiting, diarrhea, constipation
- Mouth sores and inflammation of the digestive tract
- Headache, fever, cough
- Pneumonia, nosebleeds, shortness of breath
- Rash, itching, dry skin
- Decreased appetite, altered taste
- Low potassium levels (hypokalemia)
- Low red blood cell count (anemia), low white blood cell count, low platelet count
- High blood sugar, high cholesterol, high triglycerides
- Abscesses, infections (eye, flu, viral, bronchitis)
- Abnormal kidney function, changes in kidney blood test values
- Difficulty sleeping (insomnia)
Common
Affects 1 to 10 in 100 patients
- Runny nose, gum redness and swelling, mouth pain, sore throat
- High blood pressure, red and watery eyes
- Loss of taste, bloating, difficulty swallowing
- Allergic reactions, severe skin peeling
- Blood clots (venous thrombosis), low calcium, low phosphate
- Upper respiratory tract infections, sepsis, dehydration
- Agitation, depression, numbness and tingling, dizziness, drowsiness
- Stomach bleeding, skin bleeding (bruises), petechiae
- Nail disorders, acne, yeast infections, fungal infections
- Urinary tract infections, cystitis
- Abnormal liver function tests, diabetes, muscle pain
- Pleural effusion (fluid in chest cavity)
Uncommon
Affects 1 to 10 in 1,000 patients
- Pericardial effusion (fluid around the heart, may require drainage)
- Cerebral hemorrhage in patients with brain tumors or on anticoagulants
- Eye hemorrhage
- Pulmonary embolism, intestinal perforation
- Impaired wound healing after surgery
- Inflammation and swelling of vocal cords
Rare
Affects up to 1 in 1,000 patients
- Pneumocystis jiroveci pneumonia (opportunistic lung infection)
Additional Reported Side Effects (Frequency Unknown)
- Angioedema: Swelling of the face, lips, tongue, or throat that may cause difficulty breathing
- Stevens-Johnson syndrome: Severe skin and mucous membrane reactions with painful blisters and fever
- Rhabdomyolysis: Unexplained muscle pain, tenderness, or weakness that may indicate muscle damage
If you experience any side effects, including those not listed here, inform your healthcare provider. Reporting suspected side effects helps ensure ongoing monitoring of the benefit-risk balance of this medicine. You can report side effects to your national pharmacovigilance authority (e.g., FDA MedWatch in the United States, Yellow Card Scheme in the United Kingdom, or EudraVigilance in the European Union).
How Should You Store Torisel?
Proper storage of Torisel is critical to maintaining its efficacy and safety. As this medication is prepared and administered in healthcare settings, storage is primarily the responsibility of pharmacy and nursing staff. However, understanding storage requirements can help ensure you receive a properly prepared medication.
- Unopened vials: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep vials in the original carton to protect from light.
- After first dilution (concentrate mixed with provided diluent): The 10 mg/ml solution may be stored at up to 25°C (77°F) for up to 24 hours, protected from light.
- After final dilution (mixed with 0.9% sodium chloride): Must be used within 6 hours, stored at up to 25°C (77°F), protected from light.
- Important: Do not use Torisel after the expiration date printed on the vial label and carton. The expiration date refers to the last day of that month.
Keep all medicines out of the sight and reach of children. Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to dispose of medications that are no longer needed. These measures help protect the environment.
What Does Torisel Contain?
Understanding the full composition of Torisel is important, especially for patients with known sensitivities to certain excipients. Each package of Torisel contains two vials: one with the concentrate and one with the diluent.
Active Ingredient
The active substance is temsirolimus. Each vial of concentrate contains 30 mg of temsirolimus in 1.2 ml. When combined with 1.8 ml of the provided diluent, the total volume becomes 3.0 ml with a concentration of 10 mg/ml.
Excipients
| Component | Excipient | Function |
|---|---|---|
| Concentrate | Anhydrous ethanol | Solvent |
| Concentrate | All-rac-alpha-tocopherol (E 307) | Antioxidant |
| Concentrate | Propylene glycol (E 1520) | Co-solvent |
| Concentrate | Citric acid (E 330) | pH adjustment |
| Diluent | Polysorbate 80 (E 433) | Surfactant/emulsifier |
| Diluent | Macrogol 400 | Co-solvent |
| Diluent | Anhydrous ethanol | Solvent |
Appearance
The concentrate is a clear, colorless to light yellow solution. The diluent is a clear to slightly cloudy, light yellow to yellow solution. Both solutions should be essentially free of visible particles. The medication should not be used if particles or discoloration are observed.
Torisel contains 503.3 mg of propylene glycol per 25 mg dose. If you are pregnant, breastfeeding, or have impaired liver or kidney function, do not use this medicine without medical advice. Your doctor may want to perform additional monitoring during treatment. Propylene glycol may pass into breast milk.
Marketing Authorization
The marketing authorization holder is Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium. The manufacturer is Wyeth Lederle S.r.l., Via Franco Gorgone, Zona Industriale, 95100 Catania, Italy. For additional information about this medicine, contact the representative of the marketing authorization holder in your country.
Can You Drive While Taking Torisel?
Torisel has no direct pharmacological effect on the ability to drive or operate machinery. However, several very common side effects of this medication can indirectly impair your capacity to safely perform these activities. Nausea, vomiting, and difficulty sleeping are among the most frequently reported adverse effects, and these can lead to fatigue, reduced alertness, and impaired concentration.
For patients receiving the higher dose of 175 mg for mantle cell lymphoma, the alcohol content in the formulation may also contribute to impairment. At this dose level, the ethanol content is equivalent to approximately 122 ml of beer per administration, which could affect cognitive and motor function in some patients.
If you experience any symptoms that may affect your ability to drive safely, avoid driving and operating heavy machinery until these effects have resolved. Discuss any concerns about driving with your oncology team.
Frequently Asked Questions About Torisel
Torisel (temsirolimus) is used to treat two types of cancer in adults: advanced renal cell carcinoma (kidney cancer) and previously treated mantle cell lymphoma, a type of non-Hodgkin lymphoma affecting the lymph nodes. It works by inhibiting the mTOR enzyme, which blocks tumor cell growth and the formation of new blood vessels that tumors need to grow.
Torisel is given as an intravenous infusion (drip into a vein) over 30 to 60 minutes, once weekly, in a hospital or clinical setting. It is prepared and administered by healthcare professionals. Before each infusion, you will receive an intravenous antihistamine injection approximately 30 minutes beforehand to help prevent allergic reactions. An infusion pump is the recommended method of administration.
The most common side effects (affecting more than 1 in 10 patients) include general weakness, swelling, nausea, vomiting, diarrhea, mouth sores, rash, decreased appetite, shortness of breath, infections, low blood cell counts, high blood sugar, high cholesterol, and abnormal kidney function. Your oncology team will monitor you with regular blood tests and can manage most side effects with dose adjustments or supportive medications.
No, Torisel should not be used during pregnancy unless absolutely necessary, as it may harm the developing baby. Women of childbearing potential must use effective contraception during treatment. Men with partners of childbearing potential should also use reliable contraception. Women must not breastfeed while receiving Torisel, as the drug may affect the infant's growth and development. The formulation also contains ethanol and propylene glycol, which pose additional risks during pregnancy and breastfeeding.
Torisel has significant interactions with several drug classes. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, and HIV protease inhibitors can increase temsirolimus levels, raising toxicity risk. Strong CYP3A4 inducers like rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's wort can decrease its effectiveness. ACE inhibitors may increase angioedema risk. Grapefruit and grapefruit juice must be avoided. Always inform your doctor of all medications, supplements, and herbal products you are using.
Unopened Torisel vials should be stored in a refrigerator at 2–8°C, protected from light, and never frozen. After the first dilution with the provided diluent, the solution can be kept at room temperature (up to 25°C) for up to 24 hours, protected from light. Once further diluted with sodium chloride solution for infusion, it must be used within 6 hours. In practice, storage is managed by the hospital or clinic pharmacy.
Yes, Torisel contains ethanol (alcohol) in both the concentrate and the diluent. At the standard 25 mg dose for kidney cancer, the alcohol amount is relatively small (equivalent to about 18 ml of beer). However, at the higher 175 mg dose used initially for mantle cell lymphoma, the alcohol content is more substantial (equivalent to about 122 ml of beer). This is particularly important for patients with alcohol dependency, liver disease, or epilepsy, and should be considered for pregnant or breastfeeding women.
References
- European Medicines Agency. Torisel (temsirolimus) — Summary of Product Characteristics. EMA/EPAR. Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/torisel
- Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. doi:10.1056/NEJMoa066838
- Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822-3829. doi:10.1200/JCO.2008.20.7977
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 4.2025. Available at: nccn.org
- Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706-720. doi:10.1093/annonc/mdz056
- World Health Organization. WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023.
- U.S. Food and Drug Administration. Torisel (temsirolimus) Prescribing Information. Revised 2024. Available at: FDA.gov
- British National Formulary. Temsirolimus. BNF Online. Last updated 2025. Available at: bnf.nice.org.uk
Editorial Team
Written by the iMedic Medical Editorial Team, specialists in oncology and clinical pharmacology. All content is based on current evidence-based guidelines and peer-reviewed research.
Reviewed by the iMedic Medical Review Board, an independent panel of physicians who ensure accuracy and adherence to WHO, EMA, FDA, and NCCN guidelines.
iMedic follows the GRADE framework for evidence assessment. All medical claims are supported by Level 1A evidence where available. Content is free from commercial influence and pharmaceutical company sponsorship. For more information, see our Editorial Standards.